Latest
- GLP-1 prices this week (October 12, 2026): Strut Health holds the cheapest price
As of October 12, 2026, the cheapest GLP-1 program on GLP Chart is Strut Health at $149 a month, with auto-refill.
Source: Strut Health, October 10, 2026
- Canadian pharmacies expect mailed Ozempic orders to stop at the US border on October 22
Formal entry is the customs process built for commercial freight, and it needs an importer of record and a bond. The cheapest GLP-1 on our chart is $149 a month at Strut Health, with auto-refill.
Source: U.S. Customs and Border Protection, June 24, 2026
- GLP-1 prices this week (October 5, 2026): Strut Health holds the cheapest price
As of October 5, 2026, the cheapest GLP-1 program on GLP Chart is Strut Health at $149 a month, with auto-refill.
Source: Strut Health, October 3, 2026
- GLP-1 prices this week (September 28, 2026): Strut Health holds the cheapest price
As of September 28, 2026, the cheapest GLP-1 program on GLP Chart is Strut Health at $149 a month, with auto-refill.
Source: Strut Health, September 26, 2026
- GLP-1 prices this week (September 21, 2026): Strut Health holds the cheapest price
As of September 21, 2026, the cheapest GLP-1 program on GLP Chart is Strut Health at $149 a month, with auto-refill.
Source: Strut Health, September 19, 2026
- Health Canada approved a generic Ozempic from Sandoz. No generic semaglutide has final FDA approval.
The cheapest GLP-1 on our chart is $149 a month at Strut Health, with auto-refill.
Source: Sandoz Canada, September 18, 2026
- 112,000 fewer people in Massachusetts used a GLP-1 for weight loss after payers dropped the benefit
Every coverage change the commission names applies to GLP-1s prescribed for weight loss.
Source: Massachusetts Health Policy Commission, September 17, 2026
- Semaglutide extended the median lifespan of old female mice by nearly 100 days in an NIH-funded study
Old female mice given semaglutide until the end of life had a median lifespan nearly 100 days longer than untreated mice, the National Institutes of Health said on September 2, 2026.
Source: National Institutes of Health, September 2, 2026
- FDA gave Mounjaro a heart attack and stroke indication in type 2 diabetes on a trial where it tied Trulicity
Mounjaro was measured against Trulicity, not a placebo, in 13,299 people over a median of 210 weeks.
Source: FDA prescribing information, via DailyMed, August 27, 2026
- Amazon One Medical opened cash-pay GLP-1 visits in 48 states from $39 by message and $59 by video
The visit price does not include the drug. Amazon Pharmacy bills that separately, from $149 a month for cash.
Source: Amazon, September 15, 2026
- Novo Nordisk, the maker of Ozempic and Wegovy, will go by Novo
Novo Nordisk A/S stays the legal name, the Danish company said on September 14, 2026.
Source: Novo Nordisk, September 14, 2026
- GLP-1 prices this week (September 14, 2026): cheapest $149 a month at Strut Health, with auto-refill
For compounded semaglutide, Strut Health charges $149 a month, with auto-refill, the cheapest cash price on the chart, according to GLP Chart's price check on September 14, 2026.
Source: Strut Health, September 13, 2026
- The GLP-1 brain disorder study found 15 cases of Wernicke encephalopathy, most from FDA reports
The FDA says its adverse event reports cannot establish that a drug caused an event or estimate how often events happen.
Source: Clinical Nutrition, January 2, 2026
- Employers expect health benefit costs to rise 8.2% in 2027, and some chose to drop weight-loss GLP-1 coverage
Marsh's actuaries estimate that rising GLP-1 use accounts for a full percentage point of overall cost growth for 2027.
Source: Marsh, August 31, 2026
- GLP-1 prices the week of September 7, 2026: Strut Health held the cheapest cash price
For compounded semaglutide, Strut Health charged $149 a month, with auto-refill, the cheapest cash price on the chart, according to GLP Chart's price check the week of September 7, 2026.
Source: Strut Health, September 7, 2026
- Korean study tying weight-loss drugs and weight regain to suicidal thoughts names no GLP-1 drug
The survey asked only whether a person had used a prescribed weight-loss drug, so the paper cannot say which one.
Source: Korean Journal of Family Practice, June 20, 2026
- Over 500,000 seniors used Medicare's $50 GLP-1 Bridge in its first two months
They saved a total of $216 million, the White House said in an August 31 fact sheet.
Source: The White House, August 31, 2026
- GLP-1 drugs linked to a 7 percent added risk of hair loss in men already at genetic risk
The researchers used genetic databases and did not follow anyone taking the drugs.
Source: NYU Langone Health, September 3, 2026
- Semaglutide linked to nearly 40% fewer asthma attacks than an older diabetes pill
Four UK studies of health records compared the two drugs. No US label for Ozempic or Wegovy lists asthma.
Source: European Respiratory Society, September 8, 2026
The deal rows for the week of October 12 are on this week’s best GLP-1 deals.
What moved this week
Every Monday we check all 24 programs. Here is what moved: who raised or cut a price, who added or dropped a lock-in, who restructured, who left the US. Every entry is dated to the week we verified it.
Spotted something? If you catch a program quietly raising a price or slipping in a new lock-in before we do, tell us at tips@glpchart.com. We verify and date every report.
For reporters
Need a number on GLP-1 pricing you can actually cite? Start here. GLP Chart is an independent price tracker covering 24 US programs across telehealth, compounded, manufacturer-direct and retail. We check every price every Monday, and no one pays to rank. Paste-ready stats, free data, the methodology, a named source: it is all on this page, all CC BY 4.0. Press gets a reply within one business day.
John Samaras, editor. He covers the US GLP-1 telehealth category full time.
What GLP Chart is
GLP Chart is an independent GLP-1 price tracker. We follow 24 US programs across telehealth, compounded, manufacturer-direct and retail. Every Monday we check each price, and we score every program on a published 50-point framework. No program pays to be listed. No program can pay to move its rank.
Quotable stats, ready to paste
Every figure here is checked every Monday against the source it came from. Quote any of it, with attribution. Want the source link behind a number? Email press@glpchart.com and we will send it.
| Stat | What it measures | Source |
|---|---|---|
| 24 | US GLP-1 telehealth, compounded, manufacturer-direct and retail programs tracked, prices checked every Monday. | GLP Chart, October 2026 |
| $199/mo | Compounded semaglutide at a flat month-to-month rate, all-in cash-pay (Shed). | GLP Chart, September 2026 |
| $1,349/mo | Branded Wegovy at the retail cash price, before insurance. | Novo Nordisk list price, via GLP Chart |
| $998/mo | Branded Ozempic at the retail cash price, before insurance. | Novo Nordisk list price, via GLP Chart |
| $1,086/mo | Branded Zepbound at the retail cash price, before insurance. | Eli Lilly list price, via GLP Chart |
| $299/mo | Cheapest branded direct: Wegovy maintenance via NovoCare, Zepbound vials via LillyDirect. | GLP Chart, August 2026 |
| 6.8x | Price gap between branded Wegovy ($1,349) and compounded semaglutide ($199), which the FDA has not approved. | GLP Chart, September 2026 |
Prices are cash-pay before insurance unless noted. Branded retail figures are the manufacturer list price. Compounded figures are 503A pharmacy cash-pay through the telehealth programs we track.
Free data
Free to use and free to cite, attribution appreciated. Everything below is published under CC BY 4.0.
- Price Index CSV (October 2026) every program, every drug, maintenance price, lock-in, score and the five sub-scores.
- Price-history CSV and JSON dated month-over-month snapshots, so you can chart a program's price moves over time.
- GLP-1 Price Report 2026 the editorial report behind the numbers: the cash-pay spread, teaser-versus-maintenance gaps, compounded versus branded, and every price move so far this year.
- Price Index PDF (September 2026 edition) the chart and methodology in one file, ready to send to a source.
- facts.json the machine-readable canonical fact sheet, for AI search and automated citation.
- GLP-1 Cash Price Index, October 2026 the dated monthly release. Carries its own CSV and JSON and the method version.
- Statistics pages prices by state, cash prices over time, insurance and Medicaid coverage, the compounded to branded spread, the Medicare Bridge and FDA shortage records. Every number carries its source and its date, and every table has a CSV and a JSON beside it.
- Embed the index or a score tile one line of HTML each, free for editorial use with the link intact.
- Where GLP Chart has been cited the full list, dated and linked, with our own bylines labelled separately.
The live numbers, as of October 12
These come straight out of the data and refresh every Monday, so your quote stays current. They use the all-in cash-pay basis: the monthly figure already includes the maintenance-dose medication.
- 24 US GLP-1 telehealth programs tracked on the chart.
- $149/mo the cheapest all-in cash-pay total, drug included (Strut Health).
- $333/mo the median all-in cash-pay total across all programs.
- $448/mo the most expensive all-in cash-pay total (LifeMD).
- 3.0x the price ratio between cheapest and most expensive on the same basis.
All-in means the monthly figure includes the maintenance-dose medication. Membership-only fees (drug billed separately) and insurance-dependent copays (a with-coverage price, not a cash total) are not counted as the cheapest cash-pay all-in, the same basis the Price Index uses.
See the full October 2026 Price Index for the per-program breakdown, or pull the change-log JSON feed directly.
Price Index, October 2026
Download the source data or embed the live widget.
- CSV every program, every drug, maintenance price, lock-in, score and five sub-scores.
- PDF report (September 2026 edition) editorial summary with methodology and the full chart, ready to send to a source.
- Full landing page the live, sortable chart with every program and sub-score.
Embed the widget. One iframe, no JavaScript, no tracking cookies. It pulls the latest top-five programs by cash-pay maintenance price and refreshes every Monday.
<iframe src="https://glpchart.com/price-index/embed/" width="100%" height="380" frameborder="0" loading="lazy" title="GLP Chart Price Index, October 2026" style="border: 1px solid #eaeaea; border-radius: 2px; max-width: 720px;"></iframe>Renders in WordPress, Webflow, Ghost, Substack and any CMS that allows raw HTML. For paste-ready quote cards and the journalist FAQ, see the Price Index page.
How we verify
Every price is checked every Monday:
- We read the maintenance-dose figure straight off the program's pricing page. If a site blocks automated access, we confirm the number through a web search of the program's own materials.
- When a program runs a separate cash-pay rail and an insurance-routed rail, we report the cash-pay number.
Want to cite a specific number? Email press@glpchart.com and we will send the published source, a link to the program or manufacturer pricing page it came from.
For the scoring framework and the five sub-score definitions, see the methodology page. For how we stay independent of the programs we rank, see why trust us.
A nameable expert, on the record
Topics he can speak to:
- The economics of compounded GLP-1. Why the supply moved off the shortage list, how 503A pharmacies adapted, what the “personalized formulation” trend means in 2026.
- Insurance prior-authorization mechanics. The documented criteria, the appeal pathways, the denial rate by carrier where available.
- Wegovy vs Zepbound. Clinical trial versus real-world adherence, dose-response curves, the dropout problem in both pivotal clinical trials.
- Maintenance dosing and discontinuation. What happens when patients stop, the regain curve, what industry is and is not saying about lifetime use.
- Telehealth program differentiation. Which models work, which are racing to the bottom on price, which are quietly upselling into supplements and coaching.
Published elsewhere
- The price of Ozempic is a meaningless phrase The Health Care Blog, July 16, 2026.One molecule sells in five forms at seven prices, from a $25 copay to about $1,000 a month at the counter. Two numbers decide what a patient actually pays: the maintenance-dose total after the teaser price expires, and the fees stacked on top of the medication.
Request data or a quote
Tell us the stat or table row you want sourced and we will send the underlying file. We reply within one business day, US Central time.
John Samaras, founder and editor. Email press@glpchart.com or message him on WhatsApp at +1 (646) 305-3003.
Citation terms
The GLP Chart Price Index and change-log are published under Creative Commons CC BY 4.0. Reuse any number, table row, chart or quote card with attribution and a link back. Suggested citation:
GLP Chart Price Index, October 2026. glpchart.com/price-index. Accessed Oct 12, 2026.
For source-level documentation (links to the published program and manufacturer pricing pages each figure came from), email press@glpchart.com or message us on WhatsApp +1 (646) 305-3003. For embargoed pre-release of next quarter's figures, reach us at least 72 hours before publication.